Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood Advances, 2020 - hal.science
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - europepmc.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood Advances, 2020 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun… - Blood …, 2020 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
[PDF][PDF] Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - 2020 - scholar.archive.org
Diffuse large B-cell lymphoma (DLBCL) and other non-Burkitt aggressive B-cell non-
Hodgkin lymphomas (NHLs) are curable with front-line immunochemotherapy. However …
Hodgkin lymphomas (NHLs) are curable with front-line immunochemotherapy. However …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood Advances, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Chimeric antigen receptor (CAR) T-cell therapy
has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have …
has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - hal.univ-lorraine.fr
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
[HTML][HTML] Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - europepmc.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …